Search results
Results from the WOW.Com Content Network
The first lawsuit in the United States against DePuy Orthopaedics was filed on June 15, 2010. [citation needed]Through the multidistrict litigation process, the cases were centralized in different courts depending on the exact implant at issue.
Total hip replacement is most commonly used to treat joint failure caused by osteoarthritis.Other indications include rheumatoid arthritis, avascular necrosis, traumatic arthritis, protrusio acetabuli, [5] certain hip fractures, benign and malignant bone tumors, [6] arthritis associated with Paget's disease, [7] ankylosing spondylitis [8] and juvenile rheumatoid arthritis. [9]
In the second trial, an Illinois jury returned a verdict in favor of DePuy in a lawsuit brought by a nurse who had sought $5 million in damages. [ 7 ] On June 14, 2012, Johnson & Johnson completed the acquisition of Synthes , which was integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson. [ 8 ]
A multistate team of litigators helped to negotiate a settlement with medical technology firm Stryker Corp. on Friday. Stryker, a Fortune 500 company, had been faced with multidistrict as well as ...
In August 2010, DePuy recalled its hip replacement systems ASR XL Acetabular Hip Replacement System and ASR Hip Resurfacing System due to failure rates and side effects including metallosis. The recalls triggered a large number of lawsuits against DePuy and its parent company Johnson & Johnson upon claims that the companies knew about the ...
Hip replacement can be performed as a total replacement or a hemi (half) replacement. A total hip replacement consists of replacing both the acetabulum and the femoral head while hemiarthroplasty generally only replaces the femoral head. Hip replacement is currently the most common orthopaedic operation, though patient satisfaction short- and ...
McMinn is also the inventor of several other prostheses for the hip [6] [7] [8] and knee. [citation needed] Derek McMinn is the author of Modern Hip Resurfacing (ISBN 978-1848000872), published in 2009.
UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...